Solasia Pharma K.K. (FRA:9SO)

Market Cap	48.17M -5.9%
Revenue (ttm)	2.33M +35.8%
Net Income	-4.76M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	24
Open	0.1600
Previous Close	0.1540
Day's Range	0.1600 - 0.1600
52-Week Range	0.1320 - 0.2420
Beta	n/a
RSI	55.59
Earnings Date	May 13, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 23
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9SO

Financial Performance

In 2025, Solasia Pharma K.K.'s revenue was 429.00 million, an increase of 35.76% compared to the previous year's 316.00 million. Losses were -876.00 million, -54.87% less than in 2024.

Financial numbers in JPY